It’s time to renew your lease. Are you ready to negotiate? If you’re like many practice owners, the answer is no. “Lease renewals are the No. 1 transaction in all of commercial real estate—for every new lease, there are 20 or 30 lease renewals happening—but it is the transaction that often receives the least amount of attention,” says Colin Carr, founder and CEO of CARR Healthcare, a nationwide...
It’s time to renew your lease. Are you ready to negotiate? If you’re like many...
Laser-assisted drug delivery is being used in multiple specialties to improve outcomes...
In an effort to help private practices and large healthcare organizations protect...
Canfield Scientific’s VECTRA H2 offers an all-in-one portable lightweight 3D...
Topix Pharmaceuticals' Replenix Pure Hydration Plumping Lip Treatment Broad...
Capture consistent before-and-after images with FotoFinder’s new Automated...
Epionce Renewal Calming Cream from Episciences soothes sensitive, eczema-...
 “Is it safe and effective to initiate port-wine stain laser treatments without general anesthesia in infancy?” This is the question researchers Roy G. Geronemus, MD, et al, sought to answer in their new study on the use of the Candela VBeam pulsed dye laser, which was published in the April...
|
 Pulse Biosciences has made a Premarket Notification 510(k) submission to the U.S. Food and Drug Administration (FDA) for its CellFX System, which features the company’s proprietary Nano-Pulse Stimulation (NPS) technology. The filing requests clearance of the CellFX System for commercial use in...
|
“Is it safe and effective to initiate port-wine stain laser treatments without general anesthesia in infancy?” This is the question researchers Roy G. Geronemus, MD, et al, sought to answer in their new study on the use of the Candela VBeam pulsed dye laser, which was published in the April issue of JAMA Dermatology.
After analyzing the outcomes of 197 infants with port-wine stains who underwent laser treatment during infancy (mean age at the time of first treatment was 3.38 months and the mean number of treatments was 9.8), they found that two-thirds of patents achieved greater than 75 percent clearance with no scarring or permanent pigmentary changes.
The Vbeam laser’s dynamic cooling spray allowed the physicians to treat the infants without the use of general anesthesia. “Because of the tolerability of the Vbeam laser, we are able to provide infants and children with treatment without having to put them under general anesthesia,” said Dr. Geronemus. “Treating these skin conditions early on avoids the physical and psychological impact of having a vascular birthmark on the face and body as children develop. In some cases, patients were treated within days of being born and in many cases, we saw complete...
Pulse Biosciences has made a Premarket Notification 510(k) submission to the U.S. Food and Drug Administration (FDA) for its CellFX System, which features the company’s proprietary Nano-Pulse Stimulation (NPS) technology. The filing requests clearance of the CellFX System for commercial use in common dermatologic procedures to remove general benign lesions, including sebaceous hyperplasia (SH) and seborrheic keratosis (SK).
The request is based on studies that showed positive outcomes for both SH and SK. In a clinical trial of the CellFX for SKs, presented by Thomas Rohrer, MD, at the 2018 ASLMS conference, application of NPS resulted in ‘clear’ or ‘nearly clear” outcomes in 82% of 174 treated lesions (58 subjects) after 106 days. A second clinical trial of CellFX for SH, presented at the 2019 American Academy of Dermatology conference by Gilly Munavalli, MD, found that 221 of 222 (99.5%) facial SH lesions treated with NPS energy were rated as clear or mostly clear by clinical investigators 60 days post treatment.
The company notes that FDA guidance suggests the goal for FDA 510(k) review is 90 calendar days, not including time required by the company to respond to additional information requests.
“We...
Ortho Dermatologics is now accepting applications for its 2019 Aspire Higher scholarship program, which will award $90,000 total to nine students who have been treated for a dermatologic condition.
To apply for the scholarship, students are required to share an essay about their experience of living with a dermatologic condition, as well as the role that a dermatologist, physician assistant or nurse practitioner played in helping treat them.
Scholarships are open to applicants or current attendees of a two- or four-year college, university or advanced (post-high school) vocational or technical school, and are available in three categories:
“At Ortho Dermatologics, our passion for dermatology is fueled by our understanding of the tremendous impact the profession can have on patients’ lives,” said Bill Humphries, president, Ortho Dermatologics. “Every year, we are inspired by the...
The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.
The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.
The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »
Merz Aesthetics has begun commercial shipment of the Cellfina System, indicated for long-term improvement in the appearance of cellulite in the buttocks and thighs, to aesthetic practices in the U.S.
Cellfina combines proprietary technology with minimally invasive subcision to treat the primary structural cause of dimpled cellulite. Results of the procedure last at least two years—in clinical trials, patient satisfaction with their treatment results improved from 94% at one year to 96% at the two-year mark. The most common side effects reported were soreness, tenderness and bruising... more »
